DALESANDRO MARGARET

CIK 00012088536 companiesPENNINGTON, NJ

SEC Profile

Transactions

Companies

Filings

CIK

0001208853

Recent Transactions

20 trades

Disposition to Issuer
Ambrx Biopharma, Inc.
Restricted Stock Units
2024-03-07−17,857→ 0 total
Disposition to Issuer
Ambrx Biopharma, Inc.
Restricted Stock Units
2024-03-07−10,119→ 0 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2024-02-29+35,000→ 35,000 total
Award
SEELOS THERAPEUTICS, INC.
Stock Option (right to buy)
2024-01-04+1,666→ 1,666 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2023-11-06+14,110→ 20,001 total
Award
Ambrx Biopharma Cayman, Inc.
Ordinary Shares
2023-09-01+125,000→ 125,000 total
Award
Ambrx Biopharma Cayman, Inc.
Ordinary Shares
2023-09-01+70,833→ 70,833 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2023-08-25+1,472,692→ 1,472,692 total
Award
SEELOS THERAPEUTICS, INC.
Stock Option (right to buy)
2023-01-05+50,000→ 50,000 total
Award
Skye Bioscience, Inc.$SKYE
Stock Option (Right to Buy)
2023-01-05+250,000→ 250,000 total
Purchase
SEELOS THERAPEUTICS, INC.
Common Stock
2022-05-26$0.60/sh+35,000→ 35,000 total
Award
SEELOS THERAPEUTICS, INC.
Stock Option (right to buy)
2022-01-05+35,000→ 35,000 total
Award
Skye Bioscience, Inc.$SKYE
Director Stock Option (Right to Buy)
2021-09-14+150,000→ 400,000 total
Award
SEELOS THERAPEUTICS, INC.
Stock Option (right to buy)
2021-09-01+42,000
Purchase
ONCOSEC MEDICAL Inc
Common Stock
2021-08-23$1.89/sh+20,000→ 20,000 total
Award
ONCOSEC MEDICAL Inc
Stock Option (Right to Buy)
2021-06-28+37,500→ 37,500 total
Award
ONCOSEC MEDICAL Inc
Stock Option (Right to Buy)
2020-09-14+25,000→ 25,000 total
Award
Skye Bioscience, Inc.$SKYE
Director Option Grant (Right to Buy)
2020-08-07+250,000→ 250,000 total
Award
ONCOSEC MEDICAL Inc
Stock Option (Right to Buy)
2020-05-29+37,500→ 37,500 total
Award
ONCOSEC MEDICAL Inc
Stock Option (Right to Buy)
2019-04-24+100,000→ 100,000 total

Companies

Recent Filings

Address

24 NORTH MAIN STREET

PENNINGTON, NJ, 08534-2218

View on SEC.gov